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Abstract
Viral infection leads to induction of pattern-recognition receptor signaling, which leads to interferon regulatory factor (IRF)
activation and ultimately interferon (IFN) production. To establish infection, many viruses have strategies to evade the
innate immunity. For the hepatitis B virus (HBV), which causes chronic infection in the liver, the evasion strategy remains
uncertain. We now show that HBV polymerase (Pol) blocks IRF signaling, indicating that HBV Pol is the viral molecule that
effectively counteracts host innate immune response. In particular, HBV Pol inhibits TANK-binding kinase 1 (TBK1)/IkB
kinase-e (IKKe), the effector kinases of IRF signaling. Intriguingly, HBV Pol inhibits TBK1/IKKe activity by disrupting the
interaction between IKKe and DDX3 DEAD box RNA helicase, which was recently shown to augment TBK1/IKKe activity. This
unexpected role of HBV Pol may explain how HBV evades innate immune response in the early phase of the infection. A
therapeutic implication of this work is that a strategy to interfere with the HBV Pol-DDX3 interaction might lead to the
resolution of life-long persistent infection.
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Introduction
Hepatitis B virus (HBV) is the prototypic member of the
hepadnavirus family and a major cause of liver diseases. An
estimated 400 million people are persistently infected with HBV
worldwide. A significant subset of these HBV carriers progresses to
severe liver disease, such as hepatocellular carcinoma, which may
cause up to one million deaths per year. Interferon and nucleoside
analogs such as lamivudine and adefovir are used to treat chronic
hepatitis B patients but have limited utility due to the adverse
effect and the emergence of drug-resistant variants, respectively
[1]. Thus, there is a clear medical need for new therapeutic
strategies.
Viral infection leads to the initiation of antiviral innate immune
responses resulting in the expression of type I interferons (IFNs),
IFNa and IFNb, and pro-inflammatory cytokines [2]. Recently,
the cellular mechanisms used to detect viruses and elicit
production of IFNs and pro-inflammatory cytokines have been
described in detail. It is now well-established that viruses, similar to
bacteria and fungi, are initially recognized by host pattern-
recognition receptors (PRRs) [2,3]. Viral nucleic acids (both RNA
and DNA) are the most important pathogen-associated molecular
patterns (PAMPs) recognized by PRRs [3]. Two families of PRRs
have been defined. The first is a subfamily of Toll-like receptors
(TLRs) that include TLR3, TLR7, TLR8, and TLR9, which are
mainly expressed in the endosomes of some cell types, especially
plasmacytoid dendritic cells. Recognition by TLRs of viral PAMPs
initiates TLR-mediated signaling pathways that culminate in the
activation of transcription factors NFkB, IRF3, and IRF7.
Specifically, TLRs recruit signaling adaptors, including TIR-
domain-containing adaptor protein inducing IFNb (TRIF). This
activates TANK-binding kinase 1 (TBK1)/IkB kinase-e (IKKe)t o
phosphorylate and activate the transcription factors IFN-regula-
tory factors (IRF) 3 and 7 [2,4]. The second family of PRRs are
comprised of the retinoic-acid inducible gene I (RIG-I)-like
receptors (RLRs), including RIG-I and melanoma differentia-
tion-associated gene 5 (MDA-5) [3]. Similar to TLRs, the
recognition of viral nucleic acids by RLRs leads to a cascade of
signaling events that result in activation of NF-kB, IRF3, and
IRF7. Specifically, RLRs recruit the signaling adaptor protein
IFNb-promoter stimulator 1(IPS-1, also known as MAVS, VISA,
or Cardif), activating the downstream TBK1/IKKe kinases, which
then phosphorylate and activate IRF3 and IRF7 [2]. The capacity
of both signaling pathways to restrict viral replication is consistent
with their downstream convergence at the TBK1/IKKe kinases
responsible for activation of IRF-3.
As stated above, viral infection leads to activation of cellular
signaling such as IRF signaling, which culminates in IFN
production. Infection by HBV appeared to be an exception. In
an acute HBV-infected chimpanzee model, Chisari and colleagues
have reported that HBV fails to induce transcription of any
cellular genes that relate to the entry and expansion of the virus,
implicating the lack of innate immune response upon HBV
infection [5,6]. By contrast to the earlier report, evidence was
accumulating, which indicated that the innate immune system is,
in fact, able to sense HBV infection. An early induction of innate
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killer cell and natural killer T cells response, was observed in two
patients with acute viral infection [7]. More recently, by using a
HepaRG cells, a permissive hepatocyte cell line for HBV infection,
Zoulim and colleagues found that HBV infection elicits a strong
innate antiviral response that leads to a significant reduction of
HBV DNA synthesis [8]. Taken together, it is conceivable that one
of viral proteins could impair innate immune response early in
infection.
Two recent reports have shown that DDX3 DEAD box RNA
helicase, which is known to be involved in diverse steps of RNA
metabolism, could augment IRF signaling via its interaction with
IKKe or TBK [9,10]. In other words, DDX3 augments TBK/
IKKe activity, which phosphorylates IRF3 and IRF7. Interesting-
ly, our group has shown that DDX3 binds to HBV Pol (P protein)
and inhibits viral reverse transcription [11]. Since DDX3 is
essential for augmentation of IRF signaling, we postulated that
HBV Pol impairs antiviral innate immune responses by inhibiting
IRF signaling via its interaction with DDX3. Consistent with the
notion, our results demonstrate that IRF signaling is significantly
inhibited by HBV Pol, a finding that defines HBV Pol as a viral
protein that counteracts antiviral pattern recognition receptor
signaling.
Results
HBV Pol inhibits IFN promoter activity
To determine if HBV proteins could impair IRF signaling and
counteract host innate immune responses to HBV infection, we
tested the ability of HBV proteins to inhibit interferon (IFN) b
promoter activity. Synthetic dsRNA mimic polyinosine-polycy-
tidylic acid (poly I:C) is recognized by TLR3 in endosomes when
added to medium [12]. To induce IRF signaling, human
hepatoma HepG2 cells, which support viral genome replication,
were transfected with one of three viral protein expression
constructs — core, polymerase (Pol), or HBx —, a TLR3
expression construct , and a reporter construct expressing
luciferase under control of the IFNb promoter (Fig. 1A). Cells
were complemented with the TLR3 expression construct because
HepG2 cells are deficient in TLR3 expression [13]. To ensure that
the physiological levels of viral proteins were attained, the amount
of the three viral protein expression constructs for transfection
were determined by cotransfection with the corresponding gene-
null HBV replicon: for HBV Pol (see Fig. S2), for core protein
(data not shown), and for HBx [14]. Two days following
transfection, cells were treated with poly I:C. Eight hours post-
poly I:C treatment, cells were harvested and luciferase activity was
measured. As anticipated, the luciferase activity was significantly
induced when cells were complemented with TLR3, compared to
that induced by poly I:C only (Fig. 1A). The data indicated that
HepG2 cells were able to recognize extracellular dsRNA and
induce IFN production when complemented with TLR3. More
importantly, the data showed that HBV Pol, but not other viral
proteins including HBx, significantly suppressed IFN promoter
activity (Fig. 1A). The inhibition of IFN promoter activity by HBV
Pol was somewhat unexpected, since current literature suggests
that almost all of its known function is confined to the functions –
encapsidation and viral reverse transcription – occurring inside of
nucleocapsids [15]. Further, reverse transcriptase activity of HBV
Pol appeared not to be involved in the inhibition of IFN promoter
activity, as the YMHD mutant of HBV Pol, reverse transcriptase
activity deficient mutant, remained to inhibit IFN promoter
activity (Fig. 1A). In addition, we found that three viral envelope
glycoproteins– L-HBsAg, and M-HBsAg, and S-HBsAg– had no
impact on IFN promoter activity (Fig. 1B), indicating that HBV
Pol is the only viral protein that has an inhibitory effect on IFNb
production.
To substantiate the above results in the context of viral life cycle,
the impact of viral proteins on IFNb production was examined by
using a viral replicon, which could lead to viral genome replication
when transfected [14]. Three mutants were made in which one viral
gene was inactivated per construct: (i) P (Pol)-null, (ii) C (core)-null,
and (iii) X-null (Fig. S1). An increase in IFNb production by one of
the HBV mutant constructs would point out that particular gene in
the inhibition of IFN production. Luciferase activity was monitored
followingtransfectionasdescribedabove.Thedatarevealedthatonly
cells transfected with the HBV P-null replicon construct induced a
higher level of IFN production, whereas the other three replicons,
including the wild-type, induced modest level of IFN production
(Fig. 1C). These results suggested that HBV Pol derived from the
HBV replicon – wild-type or X-null, or C-null replicon – decreased
IFN production, implicating the physiological relevance of the
findings in the viral life cycle. Intriguingly, IFN promoter activity
induced by HBV P-null replicon was significantly higher than what
was achieved by poly I:C (Fig. 1C). The implication is that some yet-
to-be known viral PAMPs derived from HBV P-null replicon could
contribute to the augmented IFN promoter activity (see Discussion).
HBV Pol inhibits IFNb promoter triggered by RIG-I/MDA5
as well as TLR3 receptor signaling
To examine whether HBV Pol could suppress diverse PAMP-
mediated signaling, poly I:C was given to cells by two distinct
routes: (i) addition to medium, and (ii) transfection via lipofectin.
The poly I:C is recognized by TLR3 in endosomes by adding it to
the cell medium, whereas it is recognized by MDA5 when it is
delivered to the cytoplasm by transfection via lipofectin [16,17].
Cells were transfected with incremental dose of the HBV Pol and
TLR3 expression constructs along with the reporter construct.
Following treatment with poly I:C in the medium, the reporter
assay result showed a dose-related decrease of IFN promoter
activity by HBV Pol expression, corroborating the above
conclusions (Fig. 2A). Likewise, when poly I:C was given by
lipofectin transfection, IFN promoter activity was similarly
decreased by HBV Pol (Fig. 2B).
Author Summary
Viral infection is sensed by the host innate immune
system, which acts to limit viral infection by inducing
antiviral cytokines such as the interferons. To establish
infection, many viruses have strategies to evade the innate
immunity. For the hepatitis B virus (HBV), which causes
chronic infection in the liver, the evasion strategy remains
mysterious. An earlier study using the chimpanzee as a
model suggested that the host innate immune system
failed to detect HBV. As a result, it was dubbed ‘‘stealth
virus’’. In contrast, subsequent studies performed in vitro
have suggested that HBV is, in fact, detected by the innate
immune system but can effectively counteract this
response. Whether HBV is detected by the innate immune
system remains controversial; however, it is widely
accepted that, regardless of detection, HBV effectively
inhibits the host innate immune response early in infection
through an unknown mechanism. The data presented here
indicate that HBV Pol (polymerase or reverse transcriptase)
blocks the innate immune response. This unexpected role
of HBV Pol may explain why HBV appears to act as a
‘‘stealth virus’’ in the early phase of the infection.
Inhibition of IRF Signaling by HBV Pol
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(SenV), a potent stimulus of the RIG-I pathway [17,18]. Cells
were transfected with the HBV Pol expression construct and the
IFN-luciferase construct. Two days after transfection, cells were
treated with 100 HA U/mL of SenV for 6 h before harvest. The
data indicated that HBV Pol diminished IFN promoter activity in
Figure 1. HBV Pol inhibits dsRNA-induced IFNb promoter activation. (A) HepG2 cells in 6-well plate were transfected with HBV Pol, core, or
HBx, and the YMHD mutant of HBV Pol expression constructs together with an IFNb luciferase reporter and TLR3 expression constructs. Cells were
stimulated with 25 mg/mL poly I:C directly added to culture medium for 8 h. Data are expressed as the mean fold induction 6 s.d. relative to mock-
treated cells. The results are representative of at least four independent experiments. (B) An experiment was performed as shown in panel (A), with an
exception of transfecting three viral surface antigen expression constructs: L-HBsAg (L), and M-HBsAg (M), and S-HBsAg (S). (C) HepG2 cells were
transfected with empty vector, WT, X-null, C-null, and P-null HBV replicon together with the IFNb reporter construct. Student’s t test was used for
statistical analysis, and a P value of ,0.05 was considered statistically significant. Poly I:C treatment was done as in panel (A). (See also Fig. S1).
doi:10.1371/journal.ppat.1000986.g001
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suggest that HBV Pol suppresses RIG-I mediated IFN production
as well as TLR3-mediated IFN production.
To substantiate the above findings, we wanted to eliminate a
possibility that the reduction of the IFN promoter activities by
HBV Pol is ascribed to the over-expression of HBV Pol. To assess
whether the HBV Pol we expressed ranges the physiological level,
we sought to show that the amount of viral DNAs synthesized via
complementation by the HBV Pol in the HBV P-null replicon
transfected cells is comparable to that of WT HBV replicon
transfected cells. To this end, HepG2 cells were transfected with
the same four increasing amount of the HBV Pol expression
construct as above to complement the P-null construct (i.e., P-) for
the viral genome replication. Viral DNAs extracted from
cytoplasmic capsids were measured by Southern blot analysis
(Fig. S2). The data showed that the amount of viral DNA
synthesized by complementation was less than that of WT HBV
replicon (Fig. S2, lane 1 versus lanes 3 to 5), suggesting that the
HBV Pol expressed in the Fig. 2A to Fig. 2C was not exceeding
physiological level. In addition, by using HepG2.2.15 cell line that
stably expresses viral proteins and support HBV replication [19],
we consistently found that IFN promoter activity induced upon
SenV (Sendai virus) infection was pronouncedly diminished in
HepG2.2.15 cells (Fig. 2D), validating the impact of HBV Pol in a
more physiological setting.
HBV Pol abrogates nuclear translocation and
phosphorylation of IRF3
Phosphorylation and nuclear translocation of IRF3 represent
hallmarks of antiviral innate immunity. To examine whether HBV
Pol inhibits the phosphorylation of IRF3, cells were transfected
with TLR3 and HBV Pol construct as indicated. Eight hours
before harvest, cells were then treated with poly I:C. Endogenous
IRF3 and its phosphorylated counterparts were detected by
Western blot analysis with anti-IRF3 and anti-phosphorylated
IRF3 (Ser396) antibodies, respectively (Fig. 3A). As anticipated,
Western blot analysis indicated that the higher molecular weight
bands of endogenous IRF3, which represent phosphorylated
IRF3, appeared when cells were treated with poly I:C (Fig. 3A,
lane 2). However, the phosphorylated IRF3 was undetectable
Figure 2. HBV Pol inhibits both dsRNA- and Sendai virus-induced IFNb promoter activation. HepG2 cells were transfected with increasing
doses of the HBV Pol expression construct, along with the IFNb luciferase reporter construct and TLR3 expression construct. Cells were stimulated
with 25 mg/mL poly I:C directly added to the medium for 8 h (A), with 25 mg/mL poly I:C transfected with lipofectin for 8 h (B), or with Sendai virus
(SenV) 100 HA/mL for 6 h (C). Data are expressed as the mean fold induction 6 s.d. relative to control levels. The results are representative of three
independent experiments, each performed in triplicate. (D) Cells (HepG2 or HepG2.2.15) were transfected with an IFNb luciferase reporter and then,
infected with Sendai virus (SenV) 100 HA/mL for 6 h before harvest.
doi:10.1371/journal.ppat.1000986.g002
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HBV Pol inhibits phosphorylation of IRF3. (see below for the
explanation for lane 4).
Nuclear translocation of IRF3 was examined by fluorescence
microscopy. Cells were transfected with the IRF3-GFP fusion protein
construct to monitor IRF3 nuclear localization (Fig. 3B). Cells were
also transfected with HBV Pol and TLR3 constructs and then treated
with poly I:C. As previously demonstrated [20], IRF3-GFP
predominantly found in the cytoplasm was induced to undergo
nuclear localization only when cells were treated with poly I:C
(Fig. 3B, panel a versus panel b). By contrast, IRF3-GFP remained
localized in cytoplasm when cells were transfected by HBV Pol and
treated with poly I:C (Fig. 3B, panel c), suggesting that HBV Pol
prevents the nuclear translocation of IRF3-GFP. Overall, these data
are consistent with the conclusion that HBV Pol inhibits the IRF
signaling. (see below for the explanation for panel d).
Figure 3. HBV Pol inhibits both phosphorylation and nuclear translocation of IRF3. (A) HEK293 cells were transfected with TLR3, HBV Pol,
and DDX3 expression construct as indicated. Two days posttransfection, cells were stimulated with poly I:C for 8 h. Western blot analysis was
performed as described in Materials and Methods. (B) HEK293 cells were transfected with GFP-IRF3, TLR3, HBV Pol, and DDX3 expression constructs,
as labeled either above or below each panel by a, b, c, and d. Two days posttransfection, cells were treated with poly I:C for 8 h. Cells were examined
by confocal microscopy.
doi:10.1371/journal.ppat.1000986.g003
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signaling
To further elucidate the specific mechanism by which viral
HBV Pol interferes with IRF activation, the impact of HBV Pol on
the signaling pathway leading to IRF activation was investigated.
To trigger RIG-I mediated IRF3 signaling, RIG-I was over-
expressed. On the other hand, TRIF is an adaptor for the TLR3
receptor and mimics TLR3 signaling when over-expressed. To
trigger TLR-mediated IRF3-signaling, TRIF over-expression was
employed. Cells were transfected with the IRF3 reporter construct
and an incremental dose of HBV Pol expression construct, along
with either RIG-I or TRIF (Fig. 4A and Fig. 4B). The data
indicated that the luciferase activity was decreased by HBV Pol in
a dose-dependent manner (Fig. 4A and Fig. 4B). Thus, we
concluded that HBV Pol inhibited both TLR-mediated and RIG-
I-mediated IRF3 signaling.
HBV Pol suppressed TBK1/IKKe triggered IRF 3/7
signaling
The TBK1/IKKe complex represents the effecter protein
kinase of IRF signaling, phosphorylating IRF3/7, when activated
by appropriate recruitment of IPS/MAVS or TRIF (Fig. 5A). The
results shown above indicated that both TLR3- or RIG-I-
mediated IRF signaling was inhibited by HBV Pol, and the
phosphorylation of IRF3/7 was blocked by HBV Pol. Thus, it is
conceivable that HBV Pol inhibits TBK1/IKKe activity. To gain
further insight into the mechanism by which HBV Pol interferes
with TLR3-mediated and RIG-I-mediated IRF signaling, we
determined if TBK1 or IKKe triggered IRF signaling could also
be blocked by HBV Pol. Cells were transfected with either TBK1
or IKKe, and IRF3 reporter construct along with incremental
doses of the HBV Pol construct. Results indicated that IRF3
signaling was triggered either by TBK1 or IKKe over-expression
and was blocked by HBV Pol in a dose-dependent manner (Fig. 5B
and 5C). Essentially identical data were obtained with an IRF7
reporter assay performed in parallel (data not shown). Thus, the
data suggested that HBV Pol exerts its inhibitory effect on TBK1/
IKKe or another downstream point in this pathway. An ISRE
reporter assay was then carried out, which indicated that HBV Pol
inhibited IKKe-triggered ISRE activation, but not IRF3-triggered
ISRE activation (Fig. 5D and 5E). These results pointed to TBK1/
IKKe as the molecular target of HBV Pol for the inhibition of IRF
signaling.
HBV Pol inhibits TBK1/IKKe activity by disrupting IKKe-
DDX3 interaction
Next, we examined whether HBV Pol inhibits TBK1/IKKe
activity directly or indirectly. Recently, two independent groups
demonstrated that DDX3 enhanced TBK1/IKKe activity via its
interaction with TBK1 or IKKe [9,10]. Additionally, we have
shown that DDX3 binds to HBV Pol [11]. Thus, we hypothesized
that HBV Pol would inhibit TBK1/IKKe activity via interaction
with DDX3. One prediction of the hypothesis is that over-
expression of DDX3 would restore IRF signaling that has been
inhibited by HBV Pol. Previous studies were limited to HEK293
and RAW264.7 macrophages; therefore, we confirmed the
importance of DDX3 for the activation of IRF signaling in
HepG2 cells following downregulation of DDX3 (Fig. S3A and
Fig. S3B). To determine if DDX3 could restore IRF3 signaling
suppressed by HBV Pol, cells were transfected by either TBK1 or
IKKe constructs along with a maximal level of HBV Pol to obtain
the highest level of IRF signaling inhibition. Cells were also
cotransfected with increasing doses of the DDX3 construct to
determine if DDX3 could restore the diminished IRF signaling.
The luciferase data revealed that the ectopic expression of DDX3
rescued the IRF signaling in a dose-dependent manner (Fig. 6A
and 6B), indicating that DDX3 antagonizes the inhibitory effect of
HBV Pol on IRF signaling. Consistently, ectopic expression of
DDX3 also rescued the phosphorylation and nuclear translocation
of IRF3 (Fig. 3A, lane 4; Fig. 3B, panel d).
Given the functional interaction between HBV Pol and DDX3
[11], it is possible that HBV Pol disrupts the IKKe-DDX3
interaction. To assess this possibility, a co-immunoprecipitation
(co-IP) following transfection of Flag-IKKe, HA-DDX3, and HBV
Pol expression constructs was performed (Fig. 6C). Similar to
previous reports [9], an interaction between IKKe and DDX3 was
observed (Fig. 6C, lane 3). Importantly, when the HBV Pol
construct was cotransfected, the IKKe-DDX3 interaction was
significantly diminished, consistent with an interpretation that
HBV Pol disrupts the IKKe-DDX3 interaction (Fig. 6C, lane 4). It
was also noted that DDX3 level was enhanced and a higher
molecular weight form of DDX3 was evident when IKKe was
Figure 4. HBV Pol inhibits both RIG-I- and TRIF-induced IRF3 activation. HepG2 cells were cotransfected with increasing doses of the HBV
Pol expression construct to determine the effect of HBV Pol on IRF3 signaling. To monitor IRF3 activation, cells were transfected with IRF3-GAL4
expression plasmid together with the GAL4-dependent pFR luciferase reporter construct. Note that 5-fold less amount of HBV Pol construct was used,
because 24-well plate, instead of 6-well, was used. To induce IRF3 signaling, RIG-I (A) or TRIF (B) expression constructs were transfected. Data are
expressed as the mean fold induction 6 s .d. relative to control levels. The results are representative of at least two independent experiments, each
performed in triplicate.
doi:10.1371/journal.ppat.1000986.g004
Inhibition of IRF Signaling by HBV Pol
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form (Fig. 6C, lanes 3 and 4); intriguingly, the similar changes of
DDX3 were also observed in the previous report [9]. It is
conceivable that the phosphorylation of DDX3 by IKKe stabilizes
DDX3. Based on the antagonistic activity of DDX3 on the
inhibitory effect of HBV Pol on IRF signaling and the disruption
of IKKe-DDX3 interaction by HBV Pol, we concluded that HBV
Pol suppresses IRF signaling by disrupting the IKKe-DDX3
interaction.
Discussion
HBV, that has been dubbed a ‘‘stealth virus’’, efficiently evades
antiviral innate immune responses early in infection [6]. However,
the underlying immune evasion mechanism remained enigmatic.
The data presented here revealed that HBV evades host innate
immune response via the inhibition of pattern recognition receptor
signaling by one of the viral proteins. Results presented here
clearly show that HBV Pol is the viral protein that blocks the
TLR3-and RIG-I-induced pattern recognition receptor signaling
in a physiologically relevant setting (Fig. 2). Further, evidence
suggests that HBV Pol suppresses IRF signaling by inhibiting
TBK1/IKKe activity, the effector protein kinase of IRF3/7
signaling (Fig. 3). Importantly, we also demonstrated that HBV Pol
inhibits TBK1/IKKe activity by disrupting the interaction
between IKKe and DDX3 (Fig. 6C). Overall, besides its inherent
catalytic role in viral reverse transcription, our results here confer a
novel immune-regulatory role to HBV Pol.
Recent evidence obtained in cultured cells showed that HBV is
capable of inducing innate host response [8,21]. However, it
remained to be learned how HBV abrogates innate immune
response. The data presented here indicate that HBV Pol blocks
Figure 5. HBV Pol blocks IRF activation by inhibiting TBK1/IKKe activity. (A) Schematic of IRF signaling pathway leading to IFN production.
TBK1 serves as a central effector kinase, but TBK1 function is also shared by the highly related IKKe kinase in some cells. DDX3 is described in an
experiment shown in Fig. 6 (see text). (B and C) HepG2 cells were cotransfected with an incremental amount of HBV Pol expression construct to
determine the effect of HBV Pol on IRF3 signaling. To induce IRF3 signaling, or TBK1 (B) or IKKe (C) expression constructs were transfected. IRF3
activation was monitored as shown in Fig. 4. (D and E) Cells are transfected as in (B and C), respectively, except that ISRE-luciferase reporter construct
was transfected, instead of the IRF reporter construct.
doi:10.1371/journal.ppat.1000986.g005
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and Fig. 2). Importantly, two experiments presented here
supported the physiological relevance of the impact of HBV Pol
on innate immune response. First, the data in Fig. 1C showed that
the inhibition of IRF signaling by HBV Pol is physiologically
relevant, since the inhibitory effect by HBV Pol was observed
under the condition, where the physiological level of viral proteins
was attained by using either wild-type or mutant HBV replicon in
HepG2 cells (Fig. 1C). This finding is further strengthened by the
evidence that IFN production was only marginally induced upon
SenV infection in HepG2.2.15 cell line compared to a parental
HepG2 cells (Fig. 2D).
Further, the data shown in Fig. 1C is significant in a few
respects. It was not unexpected that the extent of inhibition
attained by the X-null and C-null construct was comparable to
that by the wild-type replicon (Fig. 1C), since similar level of HBV
Pol would be expressed in transient transfection setting, regardless
of whether viral genome replication is induced. Secondly, the data
clearly ruled out a possibility that either X protein (i.e., HBx) or
core protein is related to the inhibition, since IFNb production in
either X-null or C-null transfected cells was comparable to that of
WT transfected cells (Fig. 1C). Thirdly, the cells transfected by the
P-null replicon mounted significantly and reproducibly higher IFN
production than that by mock DNA, suggesting that a viral
molecule derived from the P-null replicon caused augmentation of
IFNb production, in addition to what has already been induced by
poly(I:C) (Fig. 1C). It is tempting to speculate that the viral
molecule, perhaps viral RNAs, may represent viral PAMPs that
caused enhanced IFNb production.
Although the liver is an important site for chronic viral
infection, little is known about how innate immune response is
initiated in hepatocytes [13,22]. We chosen HepG2 cell for the
most experiments, a hepatoma cell line, that supports HBV
genome replication in a manner depending on HBx expression
[14]. Since TLR3 expression is deficient in HepG2 cells, IFNb
reporter assays were carried out following complementation of
TLR3; note that HepG2 cell is proficient in RIG-I mediated
signaling, which senses SenV [13]. On the other hand, unlike to
most other viruses, the PAMP signature of HBV, which are sensed
by pattern recognition receptors such as TLRs or RIG-I, has not
been defined [2]. Consequently, our analysis was limited to use of
poly I:C or SenV to trigger pattern recognition receptor signaling.
However, it should be noted that the utilization of heterologous
inducers such as poly I:C or SenV in this work does not invalidate
Figure 6. HBV Pol inhibits TBK1/IKKe via an interaction with DDX3. (A and B) DDX3 rescued IRF signaling, which was inhibited by HBV Pol.
HepG2 cells were transfected with indicated amounts of HBV Pol and DDX3 expression constructs. To induce IRF3 signaling, TBK1 (A) or IKKe (B)
expression constructs (100 ng) were transfected. IRF3 activation was monitored as shown in Fig. 4. Data are expressed as the mean fold induction 6
s.d. relative to control levels. The results are representative of at least two independent experiments each performed in triplicate. (C) HBV Pol
disrupted the interaction between DDX3 and IKKe. HEK 293 cells were transfected with Flag-IKKe, HA-DDX3, and HBV Pol expression constructs. Cell
lysates were analyzed by IP with the indicated antibodies to assess the interaction between DDX3 and IKKe. For the detection of the Flag-tagged IKKe,
mouse anti-FLAG M2 antibody (Sigma, 1:5,000) was used; anti-HA antibody (Amersham) was used to detect DDX3. The results are representative of
three independent experiments.
doi:10.1371/journal.ppat.1000986.g006
Inhibition of IRF Signaling by HBV Pol
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which lies downstream of PAMPs in IRF signaling (Fig. 5A).
Nonetheless, natural viral infection, rather than transfection,
involving susceptible human hepatocytes, merit further investiga-
tion, as recently demonstrated in HCV infection [23].
In terms of the impact of HBV Pol on IFN signaling, three
observations are worthy of mentioning. First, our preliminary data
indicated that in addition to its inhibitory effect on IRF signaling, HBV
Pol inhibits, to a lesser extent, NF-kB signaling, which also contributes
to IFNb production (data not shown). If it holds, it would suggest an
intriguingly possibility in that HBV Pol blocks IFNb production by
interfering two distinct signaling pathways, leading to IFNb produc-
tion. Work is in progress to obtain the mechanistic details. Second,
relevantly, abundant detection of HBV Pol in nonencapsidated state
has implicated that HBV Pol could contributes to viral pathogenesis or
immune evasion [24,25]. Lastly, in fact, HBV Pol has been previously
identified as one of viral proteins that confer the resistance to IFN
treatment [26,27]. It should be noted, however, that we found its
inhibitory role in IFN induction (i.e., IRF signaling), whereas the
published work found its inhibitory effect in IFN action (i.e., JAK/Stat
signaling).
DEAD-box RNA helicases constitute a large family of proteins
that comprises at least 38 members in human genome [28].
DEAD-box RNA helicases exhibit multiple roles in diverse aspects
of RNA metabolism such as transcription, pre-mRNA splicing,
RNA export, translation, and RNA decay [29]. Not surprisingly,
DDX3 has also been implicated in multiple distinct cellular
processes as well. First, DDX3 has been reported to act as a
transcriptional factor in the nucleus [30]. Secondly, DDX3 was
shown to bind to eIF4E, a translation initiation factor with cap-
binding properties, effectively suppressing translation [31]. Finally,
DDX3 has been implicated in various viral life cycles. For
instance, DDX3 was shown to be essential for nuclear export of
human immunodeficiency virus-1 (HIV-1) RNA through the Rev/
RRE pathway [32]. In addition, DDX3 supports viral replication
of hepatitis C virus (HCV) genome via its interaction with the
HCV core protein [33,34]. In contrast, DDX3 was shown to
inhibit HBV genome replication via its interaction with HBV Pol
[11]. Besides its roles in RNA metabolism, a novel function
relevant to innate immunity was recently reported by two groups
[9,10]. Although the augmentation of IRF signaling by DDX3 was
found independently by two groups, discrepancies have been
noted regarding the specific mechanism for DDX3-mediated IRF3
activation. Specifically, Bowie and colleagues [9] demonstrated
that the IKKe-DDX3 interaction is significantly enhanced upon
SenV infection with concomitant IRF3 phosphorylation, indicat-
ing that DDX3 stimulates the protein kinase activity of IKKe.I n
contrast, Decker and colleagues [10] concluded that DDX3 acts as
a transcription factor of the IFNb promoter, which is in agreement
with the transcriptional role of DDX3 reported by another study
[30,35]. Interestingly, we have demonstrated that HBV Pol
disrupts the IKKe-DDX3 interaction (Fig. 6C), which is consistent
with the conclusions of Bowie and colleagues (7). However, in-
depth analyses are needed to clarify this mechanistic issue.
Throughout evolution, viruses have developed strategies to
evade host immune response [36]. Bowie and colleagues [9]
revealed that the vaccinia virus K7 protein interferes with IRF
signaling by inhibiting TBK1/IKKe activity via a mechanism
involving its interaction with DDX3. Here, we demonstrated that
HBV Pol impairs IRF signaling by inhibiting TBK1/IKKe
activity via the HBV Pol-DDX3 interaction. Although diverse
viral proteins including structural proteins and nonstructural
proteins have evolved to evade immune response [36], it is
intriguing that viral polymerase, besides its inherent catalytic
contribution, has evolved to interfere innate immune response.
More importantly, it is interesting that vaccinia virus and HBV,
two unrelated viruses, acquired the ability to evade the immune
response by subverting DDX3 during evolution.
Administration of TLR ligands was shown to inhibit HBV
replication in a transgenic mouse model, implying that pattern
recognition receptor signaling could be exploited for the treatment
of chronic HBV infections [37]. Subsequent studies corroborated
the above findings either by transfection studies using hepatoma
cell lines [38] or by using nonparenchymal liver cells from mice
[39]. Along this line, we speculate that disruption of the HBV Pol-
DDX3 interaction by therapeutic intervention could invoke
sustained antiviral immune responses leading to resolution of
chronic viral infections. In this regard, structural elucidation of the
HBV Pol-DDX3 interaction merits further investigation.
This work was presented at the International Meeting on
Molecular Biology of Hepatitis B Viruses, which was held in
Tours, France from August 30 to September 3 of 2009 [40] and
the result similar to ours will be reported by others [41].
Materials and Methods
Cell culture, transfection
HepG2, HepG2.2.15, and HEK293 cells were grown in
Dulbecco’s Modified Eagle’s medium supplemented with 10%
fetal bovine serum (GIBCO-BRL) and 10 mg/mL gentamycin at
37uCi n5 %C O 2 and were passaged every third day. Cells were
transfected using polyethylenimine (25 kDa, Aldrich, St. Louis,
MO) as described [42]. The amount of plasmid DNA transfected
(12 mg per 60-mm plate and 30 mg per 100-mm plate) was kept
constant by inclusion of vector DNA, pcDNA3. HEK293 cells
were employed for the experiment shown in Fig. 3 and Fig. 6,
because of its higher transfection efficiency (.80%) compared to
that of HepG2 cells (,10%) (data not shown).
Reagents
Polyinosine-polycytidylic acid (poly I:C) was purchased from
Amersham. Sendai virus (SenV) was kindly provided by Prof.
Moon-Jung Song (Korea University).
Plasmids
All DNA constructs were generated by overlap extension PCR
protocols as previously described [43]. HBV Pol expression construct
encoding HBV Pol with three copies of Flag tag at its N-terminus has
been previously described [42]. The HBV replicon construct (i.e., WT)
and its X-null version has been described previously [14]. The HBV C-
null and P-null replicons have been described [42]. YMHD mutant of
HBV Pol was made by substitution of the aspartic acid residue (i.e.,
540D), a constituent of YMDD motif critical for catalysis, to histidine
(H), as previously described [44]. Three constructs that was used to
express the viral envelope glycoproteins– L-HBsAg, and M-HBsAg,
and S-HBsAg, was made by inserting the respective ORFs into
pcDNA3 (Invitrogen). The sources of the remaining plasmids are as
follows: IRF3-GAL4, IRF7-GAL4, pFR luciferase reporter, IFNb-Luc
reporter (Bowie, Trinity College Dublin, Ireland), TBK1-Flag, IKKe-
Flag (Dr. Fitzgerald, University of Massachusetts Medical School,
Worcester,MA), Flag-RIG-I (Dr.Fujita,Kyoto University),Flag-TRIF
(Akira, Osaka University), HA-TLR3 (InvivoGen), pISRE-Luc
reporter (Stratagene), HA-DDX3, AS-DDX3 (K. T. Jeang, N.I.H.),
and IRF3-GFP (Garcia-Sastre, Mt. Sinai School of Medicine).
Western blot analysis
Western blot analysis was performed as described [42]. For the
detection of the Flag tagged Pol protein, mouse anti-FLAG M2
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and phospho-specific IRF3 (Ser396) antibody (Cell Signaling) were
used to detect IRF3 and phosphorylated IRF3, respectively.
Reporter gene assays
Promoter induction and transcription factor activation were
measured using HepG2 cells seeded onto 24-well or 6-well plates
and transfected after 24 h with expression vectors and luciferase
reporter gene. For the IRF3/7 assay, an IRF3/7-GAL4 fusion
vector was used in combination with the pFR luciferase reporter,
as previously described [45].
Southern blot analysis
Southern blot analysis was performed as previously described
[46]. Briefly, the extracted viral DNA was separated by
electrophoresis through a 1.3% agarose gel in a 0.56 Tris-
acetate-EDTA buffer and then transferred onto a nylon
membrane. The nylon membrane was prehybridized and
hybridized with a
32P-labeled full-length HBV DNA probe in a
hybridization solution for 16 h at 65uC. Images were obtained
using the phosphoimager (BAS-2500; Fujifilm).
Co-immunoprecipitation
Immunoprecipitation was performed as described with modifi-
cations [47]. Briefly, after transient transfection, the medium was
removed and the cells were rinsed twice in cold PBS, incubated for
30 min at 4uC in lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1 mM EDTA, 1 mM DTT, 0.2 mM PMSF, and 1% NP-
40], and collected by scraping. Cell debris was removed through
centrifugation at 10,0006g for 10 min at 4uC. Extracts were pre-
cleared with protein G–agarose beads for 1 h at 4uC. The primary
antibody was added for 1 h at 4uC, and immunoglobulin
complexes were collected on protein G–agarose beads for 1 h at
4uC. The beads were washed five times with 1 ml of lysis buffer.
Protein complexes were recovered by boiling in Laemmli sample
buffer and analyzed by SDS–PAGE.
Confocal imaging
HEK293 cells were grown on 18-mm coverslips in 12-well
plates and transfected with 2.5 mg of total DNA. At 48 h after
transfection, cells were fixed with 3.7% formaldehyde. Slides were
mounted onto glass slides with ProLong Antifade Kit (Molecular
Probes) and examined by confocal microscopy (LSM 510 Meta;
Carl Zeiss, Germany).
Accession numbers
HBV ayw subtype: V01460 J02203
DDX3: accession NM_001356.3
Supporting Information
Figure S1 The Map of HBV replicon constructs used in this
study. WT represents the 1.2mer over-the-genome length HBV
replicon construct. Three ORFs are drawn on the pregenomic
RNA with two stem-loop structures (epsilon or e), but S ORF is
omitted for clarity. Three mutant replicon constructs including the
P-null, C-null, and X-null constructs are drawn with the
introduced stop codons denoted by dots. The ORF with dashed
line denotes the inactivated ORF.
Found at: doi:10.1371/journal.ppat.1000986.s001 (0.10 MB TIF)
Figure S2 Southern blot analysis of viral DNA isolated from
cytoplasmic capsids. Cells were transfected either with the wild-
type HBV replicon or the P-null replicon along with an increasing
amount of the Pol expression construct: 1.0, 2.0, and 4.0 mg per 6-
well plate, which are equivalent to 0.5, 1.0, and 2.0 mg per 12-well
plate, respectively. Viral DNAs isolated from cytoplasmic capsids
were analyzed by Southern blot analysis. The viral replication
DNA intermediates RC (relaxed circular) and DL (duplex linear)
DNA are denoted. In parallel, HBV Pol was examined by Western
blot analysis with anti-Flag antibody.
Found at: doi:10.1371/journal.ppat.1000986.s002 (0.37 MB TIF)
Figure S3 DDX3 is essential for TBK1/IKKe-dependent IRF
activation in HepG2 cells. To knock down endogenous DDX3, an
antisense DDX3 construct was used HepG2 cells were transfected
with either IKKe (A) or TBK constructs (B) and the IRF3 reporter
construct, along with increasing doses of the antisense DDX3
construct (i.e. AS-DDX3). IRF3 activation was monitored as
shown in Fig. 4. IRF3 signaling was blocked by AS-DDX3
transfection indicating that DDX3 is essential for IRF3 signaling in
HepG2 cells. It was noted that the impact of DDX3 on TBK-
mediated IRF3 activation was less than that seen on IKKe-
mediated IRF3 activation.
Found at: doi:10.1371/journal.ppat.1000986.s003 (0.07 MB TIF)
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